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Abstract
Background: Identification of recent HIV-infections is important for describing the HIV epidemic and compiling HIV-RNA-
setpoint data for future HIV intervention trials. We conducted a study to characterize recent infections, and HIV-RNA-
setpoint within the adult population presenting at a voluntary counselling and testing centre (VCT) in southern
Mozambique.
Methods: All adults attending the Manhic ¸a District-Hospital VCT between April and October 2009 were recruited if they had
at least one positive rapid HIV-serology test. Patients were screened for recent HIV-1 infection by BED-CEIA HIV-incidence
test. Clinical examination, assessment of HIV-RNA and CD4 cell counts were performed at enrollment, 4 and 10 months.
Results: Of the 492 participants included in this study, the prevalence of recent infections as defined by BED-CEIA test, CD4
counts .200 cells/ml and HIV-RNA .400 copies/mL, was 11.58% (57/492; 95% CI 8.89–14.74). Due to heterogeneity in HIV-
RNA levels in recently infected patients, individuals were categorized as having ‘‘high’’ HIV-RNA load if their HIV-RNA level
was above the median (4.98 log10 copies/mL) at diagnosis. The ‘‘high’’ HIV-RNA group sustained a significantly higher HIV-
viral load at all visits with a median HIV-RNA setpoint of 5.22 log10 copies/mL (IQR 5.18–5.47) as compared to the median of
4.15 log10 copies/ml (IQR 3.37–4.43) for the other patients (p=0.0001).
Conclusion: The low proportion of recent HIV-infections among HIV-seropositive VCT clients suggests that most of this
population attends the VCT at later stages of HIV/AIDS. Characterization of HIV-RNA-setpoint may serve to identify recently
infected individuals maintaining HIV viral load.5 log10 copies/mL as candidates for antiretroviral treatment as prevention
interventions.
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Introduction
HIV prevention strategies in Sub-Saharan Africa have been
mainly focused on voluntary testing and counselling centres (VCT)
and condom promotion. However, these efforts have shown
limited success in controlling the HIV epidemic and the number of
infected people continues to increase, having reached 33.3 million
[31.4–35.3 million] people living with HIV in 2009 [1]. Current
rapid serology tests employed in most resource-poor countries do
not differentiate between acute, recent and longstanding HIV
infection which have different risks of transmission.
During the early months of HIV infection, levels of HIV-RNA
in plasma and genital secretions are up to 2 log10 higher than
during the chronic phase and only comparable to end stage AIDS
[2,3]. Indeed, each log10 increase in HIV viral load has been
shown to be associated with a 2.45 increased risk of heterosexual
HIV transmission [4,5]. However, initial peak of HIV viremia
during acute HIV infection usually decreases within 6–8 weeks
and then gradually over six months to a more stable level, often
referred to as the viral load setpoint [6]. The level at which the
HIV-RNA setpoint is established is predictive of both disease
progression and the probability of HIV transmission during
chronic HIV infection [3,7]. Studies have suggested that 50% of
HIV transmissions take place in the first 6 months after infection
when HIV-RNA levels can be up to 2 log10 higher than during
chronic HIV infection [5,8]. In this view, some authors suggest
that antiretroviral treatment and/or behaviour modification
interventions focused in the initial phases of infection when
HIV-RNA levels are elevated could help in reducing HIV
transmission [9,10]. Recently, it has been proposed that
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phases of infection could be targeted for interventions to reduce
HIV transmission [10]. In line with this, early initiation of
antiretroviral treatment (ART) has recently been shown to reduce
sexual transmission of HIV among HIV serodiscordant couples
[11]. Moreover, it has been predicted that a vaccine aimed at
decreasing viral load setpoint could be an effective strategy to
prevent new HIV infections and progression to AIDS [12,13].
In the last ten years many serological assays have been
developed to distinguish between recent infections (,6 months
since seroconversion) and established HIV infections [14]. These
assays have been used to assess HIV-RNA setpoint as well as
estimate HIV incidence in a cross-sectional manner [14,15,16,17].
The most widely used assay to determine recent infections is the
BED capture enzyme-immunoassay (BED-CEIA), frequently
applied in developing countries [18,19,20,21,22,23]. However,
the assay may lead to misclassification of advanced AIDS as recent
infections [24]. To avoid these misclassifications they are usually
validated for the population screened, and the results preferably
adjusted for False Positive Rates (FPR) [25].
Characterization of recent HIV infections in African popula-
tions can aid in estimating the proportion of the population
accessing early diagnosis of HIV, as well as determining HIV viral
load setpoint levels. Indeed description of the epidemiology of
recent HIV infections may inform programs seeking to improve
VCT uptake. Additionally, identifying those individuals more
likely to transmit HIV could be useful for positive HIV prevention
efforts. Finally, assessing the HIV-RNA setpoint contributes to
understanding the dynamics of HIV transmission in a population
that is predominantly infected with HIV subtype C [26], which
has been reported to have higher levels of HIV-RNA during the
acute phase of HIV infection [27]. Little is known about the
evolution of infection for this subtype.
The objective of the study was to characterize recent infections
and HIV viral load setpoint within the HIV-seropositive adult
population presenting at a VCT in southern Mozambique.
Materials and Methods
Study population and visits
All adults attending the VCT of the Manhic ¸a District Hospital
(MDH) in Manhic ¸a, southern Mozambique, between April and
October 2009 were recruited if the first Determine (Abbott Park
Illinois, USA) serological rapid test was positive, and the
confirmatory rapid test Unigold (Trinity Biotech Co., Wicklow,
Ireland) was positive or negative or indeterminate, and if they were
permanent residents of the demographic surveillance study area.
During the study, approximately 450 individuals attended the
VCT monthly, of which an estimated 39% were residents of the
demographic surveillance study area.
The Manhic ¸a Health Research Centre (CISM) has been
conducting continuous demographic surveillance in the district
since 1996 which covered a population of 82,000 persons at the
time of this study.
Participants were screened for recent HIV-1 infection by BED-
capture enzyme immunoassay incidence assay (BED-CEIA). CD4 T
cellcountswereperformedforallparticipants,andplasmawasfrozen
for subsequent determination of HIV-RNA viral load if BED-CEIA
identified them as recently infected. Patients identified as recently
infected were invited for follow-up visits at 4 and 10 months for CD4
and CD8 T cell counts and HIV-RNA assessment. Clinical
examination and epidemiological data were recorded at each visit.
During the study period, six patients became eligible for ART
and initiated treatment (three at 4 months and another three at 10
months.). Those patients were excluded from the study when they
initiated antiretroviral therapy. In accordance with the Mozambi-
can National Antiretroviral Treatment Guidelines, ART initiation
criteria were defined as CD4+ cell count #200 cells/mL
irrespective of the clinical stage, WHO stage III with CD4cell
count #350 cells/ml, or WHO stage IV irrespective of CD4 cell
count.
Written informed consent was obtained from patients prior to
participation. The study protocol was reviewed and approved by
the Mozambican National Bioethics Committee (ref. 232/CNBS/
07) and the Hospital Clinic of Barcelona Ethics Review
Committee (ref. CEIC/2007/3943).
Laboratory procedures
BED enzyme immunoassay. Recent infections were
determined from cryopreserved plasma samples with the
commercial BED-capture enzyme immunoassay (BED-CEIA)
strictly following the manufacturer’s instructions (Calypte
Biomedical Corporation, Portland, OR 97224).
The BED-CEIA is a quantitative antibody assay that determines
the proportion of HIV-1-specific IgG antibodies in samples with
respect to total IgG antibodies; BED-CEIA detects recent
seroconversion as samples presenting low levels of HIV-1-specific
IgG considered to reflect infection within a window of approxi-
mately 6 months [15]. Seropositive samples from individuals
testing below the threshold of a normalized optical density (ODn)
of less than 0.8 are classified as recently infected, likely to have
been infected within the past 6–8 months.
HIV-RNA determinations. HIV-RNA levels were determined
from cryopreserved plasma samples with the commercial Roche
Amplicor Monitor, version 1.5 (Roche Diagnostics, Basel,
Switzerland) technique for amplification and quantification of HIV-
1 RNA. Lower limit of detection was 400 copies/mL. For the
purpose of analyses, plasma HIV-1 RNA concentrations below the
limit of detection were assigned the value of 200 copies/mL.
CD4 and CD8 counting. CD4 and CD8 counting was
performed after staining with labelled antibodies: CD4, CD3,
CD8, and CD45 in TruCount tubes (Becton Dickinson
Biosciences, San Jose, California, USA). Samples were assessed
by flow cytometry on a FACS_Calibur (Becton Dickinson).
Statistical analysis and definitions
Proportions for categorical variables were compared using the
Pearson chi-squared test. The Wilcoxon rank-sum test was used to
compare medians of continuous variables with non-normal
distribution and the Wilcoxon signed-rank test to compare paired
groups. Statistical analyses were performed using STATA version
11 (STATA Corp., College Station, Texas, USA).
Patients were considered HIV-infected when both the first
(Determine, Abbott Park Illinois, USA) and the confirmatory
(Unigold, Trinity Biotech Co., Wicklow, Ireland) rapid HIV
serology tests were positive, and indeterminate when only the first
rapid test was reactive.
Recently infected patients were defined as those individuals with
HIV-positive or indeterminate serology (as defined above) and a
BED-CEIA assay ODn reading of ,0.8, CD4 counts .200 cells/
ml and HIV-RNA levels .400 copies/mL. All recent-BED-CEIA
testing patients with CD4 counts below 200 cells/ml or Viral Load
,400 copies/mL were considered long-standing infected patients
and those with low CD4 counts (,200 cells/ml) referred for ART
initiation. CD4 count ,200 cells/ml and viral load (VL) ,400
copies/mL have been associated with misclassification of recent
infections by BED-CEIA [28].
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were defined as those individuals with HIV-RNA level at
enrollment above the median HIV-RNA level (4.98 log10
copies/mL).
Assuming that the viral load setpoint is established during the
first year of infection, we defined that viral load setpoint had been
reached in a population when the median HIV-RNA measure-
ments did not show significant differences between visits. The viral
load setpoint of each individual was then calculated as the mean of
at least two consecutive measurements. The population viral load
setpoint was expressed as median and interquartile range (IQR).
Results
Characteristics of the study population
Among 492 individuals enrolled in the study who presented at
the Manhic ¸a hospital VCT with a positive HIV Determine rapid
test, 97.7% (481/492) had a confirmed HIV positive serology and
2.23% (11/492) had an indeterminate HIV serology, as defined in
methods (Table 1).
The median age of the study population was 34 years (IQR 28–
42) ranging from 18 to 86 and patients were predominantly female
(69.30%; 341/492). Women were significantly younger than men
[median: 33 years (IQR 27–40) versus 35 years (IQR 29–46),
respectively, p=0.0012].
Epidemiology of recent HIV infection
Of the 492 individuals enrolled, 80 [16.26%; 95% CI 13.10–
19.82] were classified as having a recent infection by the BED-
CEIA assay (Table 1). Of these 80 patients, 19 (23.75%) had CD4
counts below 200 cells/ml and were considered to be advanced
HIV infections, according to the definitions applied (see methods).
In addition, four individuals (6.55%) with VL,400 copies/mL
(6.55%) were also considered long-standing infections and
excluded from the recently infected population in order to reduce
the rate of misclassification. Thus, using CD4,200 cells/mla sa
surrogate of false positivity, the FPR for recent infections was
3.86%, and adding VL,400 copies/mL to the definition, the FPR
for recent infections was 4.67%. As a consequence, the prevalence
of recent HIV infection was 12.39% (61/492), (95% CI 9.61–
15.63) or 11.58% (57/492), (95% CI 8.89–14.74), as defined by
the BED-CEIA assay and CD4 counts greater than 200 cells/mlo r
BED-CEIA and CD4 counts greater than 200 cells/ml and VL
greater than 400 copies/mL respectively. The remaining 435
(88.41%) patients were classified as having a long-standing HIV-1
infection. Due to the unknown validated FPR for BED-CEIA in
our population, we did a sensitivity analyses to assess the impact of
different FPR on the population prevalence of recent infections.
We randomly assigned FPR of 1%, 3% and 5% to the BED-CEIA
assay in our study population based on values reported in other
countries [22,23,24]. These calculations yielded prevalences of
recently infected patients of 15.26%, 13.26% and 11.26%
respectively. These values fell within close range of the confidence
interval of the prevalence of recent infections determined using
CD4,200 cells/ml and VL,400 copies/mL as surrogates of FPR
[11.58%, (95% CI 8.89–14.74)]. The remaining analysis was
performed using the CD4-VL corrected definition of recent HIV
infection.
Median HIV-RNA measurements and CD4 counts of BED-
CEIA diagnosed recently infected individuals using the CD4-VL
corrected definition are shown in table 2. Using the CD4-VL
corrected definition of recent HIV infections, among those
patients with confirmed HIV positive serology, 10.22% (95% CI
7.66–13.29) had a recent infection whereas among those with an
indeterminate HIV serology, 88.88% (95% CI 51.75–99.71) had a
recent infection.
Women had a significantly greater proportion of recent HIV
infections as compared to men (13.78% [95%CI 10.30–17.90] vs.
6.62% [95%CI 3.22–11.84] respectively, p=0.022).
The median age of the recently HIV infected population was
34.0 years (IQR 24.9–46.9), similar to the age of the long-standing
infected population [33.5 years (IQR 27.6–41.5), p=0.9]. Within
the recently infected population, the median age for women was
33.3 years (IQR 23.9–41.4), significantly younger than the median
age for men [47.4 years (IQR 30.6–54.5), p=0.030].
No patient self-reported specific symptoms characterized the
HIV-1 recent infections in the population nor distinguished them
from long-standing HIV infections (Table 3).
Immuno-virological parameters in Recent HIV infected
patients
Patients considered to be recently infected by HIV were
followed up for assessment of their CD4 counts and HIV-RNA
load. Median CD4 cell count measures at 4 months (497 cells/ml
(IQR 347–597) and at 10 months (582 cells/ml (IQR 533–758)
were not significantly different compared with values at HIV
diagnosis [(516.5 cells/ml (IQR 305–722), p=0.700 and p=0.139
respectively].
Follow-up measurements of HIV-1-RNA in recently infected
individuals showed a median viral load of 4.50 log10 copies/ml
(IQR 3.88–5.16) at 4 months post-diagnosis which was slightly
Table 1. HIV serological characteristics of the study
population (N=492).
n % (95%CI)
HIV RT positive 481 97.7 (95% CI 96.03–98.87)
HIV RT indeterminate 11 2.23 (95% CI 1.12–3.96)
BED-CEIA-recent 80 16.26% (95% CI 13.10–19.82)
BED-CEIA-recent, CD4.200 cell/ml 61 12.39% (95% CI 9.61–15.63)
BED-CEIA-recent, CD4.200 cell/ml,
VL.400 copies/mL
57 11.58% (95% CI 8.89–14.74)
RT: rapid testing. BED-CEIA: BED capture enzyme immunoassay. VL: Viral Load.
HIV positive and indeterminate serology by RT and BED-CEIA recent infection as
defined in methods.
doi:10.1371/journal.pone.0031859.t001
Table 2. Baseline virological and immunological parameters
among individuals diagnosed with recent HIV infections by
the BED-CEIA assay.
n Median (IQR)
BED, CD4.200 cells/mL
HIV-RNA log10 copies/mL 57 4.98 (4.29–5.44)
CD4 cells/ml 52* 516.5 (305–722)
BED, CD4 ,200 cells/mLo r
VL,400 copies/mL
HIV-RNA log10 copies/mL 23 5.23 (4.65–5.64)
CD4 cells/ml 23 135 (46–186)
Results are presented according to CD4 counts.
*CD4 counts available for 52/57 patients.
doi:10.1371/journal.pone.0031859.t002
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4.29–5.44), p=0.044]. At 10 months post-diagnosis, median viral
load was 4.88 log10 copies/ml (IQR 4.55–5.16), which was not
significantly different from values at baseline or at the 4 month
visit (p=0.77, p=0.34 respectively).
Because of great heterogeneity in patterns of HIV-RNA
evolution over time, recently infected patients were categorized
as having ‘‘high’’ HIV-RNA load if the HIV viral load at diagnosis
was above the median (described in methods). The group of
patients with high HIV-RNA sustained a significantly higher
median HIV viral load at all visits compared with the other
patients (Figure 1A). The interquartile ranges showed that those
individuals with high HIV-RNA levels had a lower intra-group
heterogeneity in HIV-RNA levels than did the other patients.
Within the group of patients with high HIV-RNA, a stable viral
load was maintained from diagnosis through to the 10 month
follow-up with no statistically significant differences in HIV-RNA
levels between visits (Figure 1A). Thus, individual HIV viral load
setpoint values were determined by pooling HIV-RNA data as
described in methods. The median population HIV-RNA setpoint
for the high HIV-RNA patients was 5.22 log10 copies/ml (IQR
5.18–5.47) as compared to 4.15 log10 copies/ml (IQR 3.37–4.43)
for the other patients (p=0.0001).
Median CD4 counts did not differ significantly between the
high HIV-RNA group and the other patients for all follow-up
visits. Median CD8 counts were increased in those with high HIV-
RNA levels for all follow-up visits, but a significant difference
between groups was only observed at diagnosis (high HIV-RNA
group 1152 (IQR 900–1893) vs. the other patients 894 cells/ml
(IQR 605–1379), p=0.031). In addition, the CD4:CD8 ratio at
diagnosis was lower in the high HIV-RNA group as compared to
the other patients (p=0.0027) (Figure 1B).
Discussion
Our findings show that 11.58% of clients of the Manhic ¸a
Hospital VCT in southern Mozambique may be considered to have
a recent HIV infection. There was a higher prevalence in women
than in men. Assessment of HIV viral load setpoint in recently
infected individuals revealed great heterogeneity of HIV-RNA viral
load from which two patterns emerged. Individuals with HIV viral
load above the median at enrollment (.4.98 log10 copies/mL)
sustaineda highHIV-RNAleveland asetpointof5.22log10copies/
mL. This contrasted with individuals with an initial HIV viral load
below the median and a viral load setpoint of 4.15 log10 copies/mL.
The prevalence of recently infected HIV patients (11.58%)
among HIV-seropositive VCT clients in Manhic ¸a was similar to
that of other African countries [19] but lower than that observed
in European countries such as Switzerland where a prevalence of
37% of recent HIV infections was reported in VCT clients as
determined by the BED-CEIA [29]. A low prevalence of recent
infections suggests that a large proportion of the Manhic ¸a
population attends the VCT at later stages of HIV/AIDS. Thus,
recently infected individuals, who are more likely to transmit, may
have lower VCT uptake. This does not include pregnant women
who undergo HIV testing in the Manhic ¸a antenatal clinic (ANC).
Clients of the ANC are younger with a median age of 24 years and
may have a higher prevalence of recent HIV infections than those
attending the general VCT [30,31,32]. Late diagnosis of HIV has
been observed in other African countries, and it is likely due to a
poor access to health care in these settings [33]. Late presentation
is associated with a higher mortality after ART initiation [34] and
this has led to piloting new HIV testing approaches to increase
uptake, including mobile units, provider-based and home-based
counselling and testing [35].
The gender and age distribution of recent HIV infection
observed in our study is likely to be a reflection of the HIV
epidemic and trends in VCT uptake in the area. We observed that
the prevalence of recent HIV infections was significantly higher in
women as compared to men, corroborating findings of increased
HIV prevalence in women in sub-Saharan Africa [1,36]. In our
study, recently infected men were significantly older, almost 10
years when comparing with recently infected women. This may
reflect migration trends for young healthy men from Manhic ¸a
working in South Africa [37]. This would most probably lead to
underrepresentation of young men in the recently infected
population, and overrepresentation in more advanced stages of
disease when HIV progression may impede seeking employment
in South Africa. These age and gender distributions suggest that
other approaches to HIV testing are needed to increase earlier
diagnosis of HIV in all age groups with particular attention to
VCT uptake in men.
In terms of clinical signs and symptoms that could potentially
differentiate recent from long-standing HIV infections, we did not
observe any non-specific self-reported signs associated with either.
It has been shown that nonspecific flu-like syndromes may help to
identify patients during the acute phase of the infection which lasts
up to 6 weeks [38,39,40,41]. However, although patients may
have high HIV viral loads over a longer period of time, nonspecific
patient-reported symptoms do not appear to distinguish recent
from longstanding HIV infected patients in our population. This
study did not include clinical exploration for opportunistic
infections.
HIV viral load setpoint has been loosely defined as a stable viral
load level established within the first year after seroconversion [6].
However, in the literature the establishment time of this HIV viral
load setpoint has been defined at various time points ranging from
4 months to 24 months post-infection [7,42,43,44]. We estimated
the HIV viral load setpoint over the 1
st year of HIV infection. In
our study population, HIV-RNA levels of patients classified as
recently infected remained elevated throughout the follow up. In
addition, those with HIV-RNA levels greater than the median
(4.98 log10 copies/mL) at diagnosis maintained HIV-RNA levels
above 4.98 log10 copies/mL during the first year after infection
with an estimated viral load setpoint of 5.22 log10 copies/mL.
These individuals may be more rapid progressors and could have
an increased risk of transmitting HIV. There is indeed agreement
that higher HIV-RNA setpoints are associated with faster
progression to AIDS and increased risk of HIV transmission
[7,45,46,47]. Individuals with HIV viral load above 4.91 log10
copies/mL have been suggested to progress to AIDS as quickly as
3 years after infection [48], and those patients with HIV-RNA
Table 3. Self-reported clinical symptoms according to status
of HIV infection.
Reported
symptom
Recent HIV
infection*(n=57) n
(%)
Long-standing HIV
infection (n=435) n
(%) P-value
Loss of weight 32 (56.14) 277 (63.82) 0.30
Cough 20 (35.09) 176 (40.46) 0.47
Diarrhea 3 (5.26) 43 (9.89) 0.33
Common Cold 15 (26.32) 141 (32.41) 0.45
*Recent HIV infection defined by BED-CEIA, CD4 counts .200 cell/mla n d
VL.400 copies/mL.
doi:10.1371/journal.pone.0031859.t003
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HIV transmission rates [4].
It has recently been suggested that individuals maintaining
HIV-RNA viral loads greater than 4.7 log10 (50000) copies/mL
could be a target for antiretroviral treatment for prevention to
reduce HIV transmission [10]. The percentage of individuals with
HIV viral loads above 4.7 log10 copies/mL in Botswana was
suggested to be approximately 25%–30% both in the general
population and in antenatal clinics tested by rapid serology tests
[10]. According to this approach, up to 50% of recently infected
individuals in the present study could be candidates for
antiretroviral treatment for prevention and suggests that screening
for recent HIV infections may identify a greater proportion of
individuals with elevated viral load.
Our results showed that patients with elevated viral load had
higher CD8 T-cell counts and lower CD4:CD8 T-cell ratios at
diagnosis. Other studies have suggested that within HIV-1 subtype
C infected patients, those individuals who maintain a higher viral
load setpoint display lower levels of CD4 cells [27]. We did not
observe these low levels of CD4 counts in the group maintaining
higher HIV-RNA viral load, however these patients showed
decreased CD4:CD8 ratios over the year of follow-up.
This study had several limitations. Although the BED-CEIA
assay is widely used tool, it has not been validated for subtype C. It
has been suggested that the BED-CEIA period of recency may be
wider for subtype C than for subtype B. The recency window for
subtype B is 162 days and could be up to 203 days for subtype C
[49]. Nevertheless, several studies have used BED-CEIA for
measuring recent infections and estimating incidence in countries
where HIV subtype C is the major subtype [18,19,21,22,25,50].
We considered a broader recency window of up to 8 months.
However it is important to emphasize that the present study did
not have the aim of measuring incidence but only a prevalence of
recent infections in the area.
Another limitation is that BED-CEIA is known to overestimate
the proportion of recently infected individuals which may lead to
misclassification of advanced AIDS as recent infections [51]. To
avoid this misclassifications a false positive rate (FPR) can be
calculated for each population studied. However, the calculation
requires comparison with longitudinal incidence studies, which
were not available for the Manhic ¸a population. We thus used CD4
counts and HIV-RNA levels as surrogates of FPR. Hence, our
results were based on the assumption that BED,0.8n O.D.,
CD4.200 cells/ml and VL.400 copies/mL identifies recent
infection. We, as other authors, considered those individuals
reading as recent HIV infections by BED-CEIA but with
CD4,200 cells/mlo rV L ,400 copies/mL as false recent
infections [18,28,50,52]. This is based on the assumption that
the production of HIV-specific IgG decreases when viral
replication is suppressed or in the presence of severe immunosup-
pression. This in turn can lead to a low proportion of specific HIV-
IgG relative to total IgG giving a false recent infection by the
BED-CEIA [28]. Nevertheless, we cannot exclude that a small
number of advanced AIDS patients with CD4.200 cells/mlo r
VL.400 copies/mL were misclassified as recent infections which
could lead to an overestimation of both the prevalence of recent
Figure 1. Evolution of median HIV-RNA load and CD4:CD8 ratios in recently infected patients. HIV-RNA load (A) and CD4:CD8 ratios (B) in
patients with high HIV-RNA as compared to the other patients. Median and interquartile range are shown. HIV-RNA viral load groups are defined as
described in methods. P-values are from Wilcoxon rank sum test between groups as follows: *p=0.0001, **p=0.038, *** p=0.002. P-values from
Wilcoxon Signed Rank between visits did not show significant differences. Numbers denote the n for each group at each time point.
doi:10.1371/journal.pone.0031859.g001
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hand, the potential exclusion of recently infected patients with
CD4,200 cells/mlo rV L ,400 copies/mL could lead to
underestimating the prevalence of recent infected patients.
However this is less likely. Finally, the study suffered a large loss
to follow-up during the 10 months of the study leading to a low
sample size at 10 months of followup. However, the loss was equal
in both high HIV-RNA patients and those with lower HIV-RNA
levels.
In addition to the use of BED-CEIA and FPR, other approaches
such as antibody avidity tests or other detuned ELISA have been
used to estimate recent infections alone or in combination
[24,25,52]. The use of a second avidity test to identify recent
infections diminishes the likelihood of misclassifications [24],
however it may require specific technology which can limit its use
in a developing country. The approach of using the BED-CEIA
assay and CD4,200 cells/ml and VL,400 copies/mL as
surrogate markers for FPR may facilitate the identification of
recent infections in situ using the HIV monitoring tools already
available or being scaled up in many low income countries.
In summary, the present study provides data on recent HIV
infections and viral load setpoint from an area with little previous
information. Our results suggest that in a rural area of southern
Mozambique, a low proportion of individuals seek HIV testing at
early phases of HIV infection and points to a need for new
approaches to HIV testing. Our results also identify a group of
patients in early phases of HIV infection with an elevated HIV-
RNA setpoint greater than 5.0 log10 copies/mL which could be
target for ART for prevention strategies.
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